

International Union of Pharmacology: Status of the Calcitonin Gene-Related Peptide Subtype 2 Receptor

DEBBIE L. HAY, DAVID R. POYNER, AND REMI QUIRION¹

School of Biological Sciences, University of Auckland, Auckland, New Zealand (D.L.H.); School of Life and Health Sciences, Aston University, Birmingham, United Kingdom (D.R.P.); and Department of Psychiatry, Douglas Hospital Research Centre, McGill University, Montréal, Québec, Canada (R.Q.)

Abstract	000
I. Introduction	000
II. Studies on cloned receptors	000
A. Calcitonin gene-related peptide and adrenomedullin receptors	000
B. Calcitonin and amylin receptors	000
III. Conclusions	000
References	000

Abstract—Historically, calcitonin gene-related peptide (CGRP) receptors have been divided into two classes, CGRP₁ and CGRP₂. After the cloning of calcitonin receptor-like receptor (CLR) and receptor activity-modifying proteins (RAMPs), it became clear that the CGRP₁ receptor was a complex between CLR and

RAMP1. It is now apparent that the CGRP₂ receptor phenotype is the result of CGRP acting at receptors for amylin and adrenomedullin. Accordingly, the term “CGRP₂” receptor should no longer be used, and the “CGRP₁” receptor should be known as the “CGRP” receptor.

I. Introduction

Heterogeneity among calcitonin gene-related peptide (CGRP²) receptors was first detected in 1989, when it was shown that the truncated CGRP antagonist, CGRP₁₂₋₃₇, preferentially antagonized the chronotropic and ionotropic actions of CGRP on the guinea pig atrium but not its ability to inhibit contraction of the electrically stimulated rat vas deferens. In contrast, the linear CGRP agonist, Cys(ACM)^{2,7}-hαCGRP, selectively activated CGRP receptors on the vas deferens (Dennis et al., 1989). Based on these data, it was suggested that there

were two subtypes of CGRP receptor, CGRP₁ and CGRP₂. Subsequent work with the antagonist CGRP₈₋₃₇ confirmed these observations (Dennis et al., 1990). CGRP₁ receptors were classified as being antagonized with high potency by CGRP₈₋₃₇, whereas CGRP₂ receptors were less sensitive to the effects of this antagonist. The interpretation of data with Cys(ACM)^{2,7}-hαCGRP is complicated by the fact that it is a partial agonist (Waugh et al., 1999), but observations with CGRP₈₋₃₇ have demonstrated that a broad range of CGRP₈₋₃₇ affinities can be observed within a single species (Fig. 1a). A more limited range of studies with the nonpeptide antagonist BIBN4096BS also suggests heterogeneity in receptors responding to CGRP (Fig. 1b). Thus, there is good evidence that CGRP can act via more than one receptor when applied pharmacologically. When the International Union of Pharmacology nomenclature subcommittee previously considered CGRP receptors, that status of the CGRP₂ receptor was unclear (Poyner et al., 2002); this situation has now been clarified.

Address correspondence to: Dr. David Poyner, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK. E-mail: d.r.poyner@aston.ac.uk

¹ On behalf of the International Union of Pharmacology nomenclature subcommittee on adrenomedullin, amylin, calcitonin, and CGRP receptors (D.L.H., D.R.P., R.Q., W. Born and J. Fischer, University of Zurich, Zurich, Switzerland; P. Sexton, Monash University, Victoria, Australia; and N. Minamino and K. Kangawa, National Cardiovascular Center Research Institute, Osaka, Japan).

This article is available online at <http://pharmrev.aspetjournals.org>. doi:10.1124/pr.108.00372.

² Abbreviations: CGRP, calcitonin gene-related peptide; Cys(ACM)^{2,7}-hαCGRP, [acetamidomethyl-cysteine^{2,7}]-human α-CGRP; BIBN4096BS, N-[2-[[[5-amino-1-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[[3,5-dibromo-4-hydroxyphenyl]methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny)]]; AM, adrenomedullin; CLR, calcitonin receptor-like receptor; RAMP, receptor activity-modifying protein; CT, calcitonin; AMY, amylin.

II. Studies on Cloned Receptors

A. Calcitonin Gene-Related Peptide and Adrenomedullin Receptors

The best characterized CGRP receptor has two transmembrane-spanning components; a G protein-coupled receptor-like protein, CLR, and also an accessory protein, RAMP1. This receptor has the pharmacological




FIG. 1. Antagonist affinities on CGRP receptors. a, apparent pA₂ values for CGRP₈₋₃₇ on human cells and tissues. For CGRP receptors (CLR/RAMP1), data have been combined from studies on recombinant receptors and also SK-N-MC cells. b, apparent pA₂ values for BIBN4096BS on rat (Δ) and human (●) cells and tissues. It should be noted that because BIBN4096BS is probably an allosteric antagonist (Hay et al., 2006), the apparent pA₂ values are simply to give a guide as to its affinity at the preparations illustrated here. Data for both figures from Hay et al. (2004), updated to 2008 (Sheykhzade et al., 2004; Springer et al., 2004; Kawase et al., 2005; Nodin et al., 2005; Verheggen et al., 2005; Bailey and Hay, 2006; Gupta et al., 2006a,b; Takhshid et al., 2006; Edvinsson et al., 2007; De Mey et al., 2008; Wunder et al., 2008). In addition, an apparent pA₂ for BIBN4096BS of 14 on human pial arteries has been reported (Moreno et al., 2002). Where no error bar is shown, the result is from a single study; otherwise n = 2 to 12. HUVEC, human umbilical vein endothelial cells.

profile of a CGRP₁ receptor (McLatchie et al., 1998). Coexpression of CLR with RAMP2 and RAMP3 gives receptors that preferentially bind AM (McLatchie et al., 1998). These are the AM₁ and AM₂ receptors (Poyner et al., 2002). The AM₂ receptor, in particular, can have significant affinity for CGRP and therefore might be activated by this peptide at pharmacological concentrations (Hay et al., 2003). CGRP₈₋₃₇ can antagonize AM₁ and AM₂ receptors with estimated pA₂ values in the range of 6.0 to 7.0 (Fig. 1a); BIBN4096BS has no appreciable affinity at either of these receptors (Hay et al., 2003). Therefore, under conditions of high receptor expression, the AM₂ receptor could be activated pharmacologically by CGRP and antagonized by CGRP₈₋₃₇ with low potency; the characteristics of a CGRP₂ receptor.

B. Calcitonin and Amylin Receptors

CT receptors are activated only very weakly by CGRP so need not be considered here. On the other hand, AMY receptors can show significant affinity for CGRP. In particular, the AMY_{1(a)} receptor (insert negative CT receptor [CT_(a)] plus RAMP1), at least in transfected cells, may potentially be activated by CGRP (Kuwasako et al., 2004; Hay et al., 2005). The AMY_{3(a)} [CT_(a)/RAMP3] receptor shows activation by CGRP similar to that of the AM₂ receptor (Hay et al., 2005). Furthermore, both of these AMY receptor subtypes were shown to be weakly antagonized by CGRP₈₋₃₇. Similar observations have also been made for rat AMY_{1(a)} receptors (D. L. Hay and A. Ferner, unpublished observations). Therefore, AMY₁ and AMY₃ receptors also have the characteristics of a

CGRP₂ receptor. The AMY_{1(a)} receptors [but not the AMY_{3(a)} receptors] show significant affinity for BIBN4096BS (Hay et al., 2006) but at approximately 150-fold lower than that seen at CGRP₁ receptors (Fig. 1b).

III. Conclusions

There are now clear molecular correlates for CGRP receptors identified pharmacologically. The CGRP₁ receptor corresponds to the CLR/RAMP1 complex. The pharmacological profile of the CGRP₂ receptor can be generated by the AMY₁ receptor and, to a lesser extent, by the AMY₃ and AM₂ receptors. Accordingly, it is recommended that the “CGRP₁” receptor should now be called the “CGRP” receptor and the term “CGRP₂” receptor should not be used. There remain significant differences between antagonist affinities found on cell lines and tissues for the same receptor subtype (Fig. 1). These complicate the pharmacological identification of receptors and may relate to accessibility or stability issues of the currently available antagonists.

REFERENCES

Bailey RJ and Hay DL (2006) Pharmacology of the human CGRP1 receptor in Cos 7 cells. *Peptides* **27**:1367–1375.
 De Mey JG, Megens R, and Fazzi GE (2008) Functional antagonism between endogenous neuropeptide Y and calcitonin gene-related peptide in mesenteric resistance arteries. *J Pharmacol Exp Ther* **324**:930–937.
 Dennis T, Fournier A, Cadieux A, Pomerleau F, Jolicoeur FB, St. Pierre S, and Quirion R (1990) hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. *J Pharmacol Exp Ther* **254**:123–128.
 Dennis T, Fournier A, St. Pierre S, and Quirion R (1989) Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues: evidence for receptor multiplicity. *J Pharmacol Exp Ther* **251**:718–725.
 Edvinsson L, Nilsson E, and Jansen-Olesen I (2007) Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP

- induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. *Br J Pharmacol* **150**:633–640.
- Gupta S, Mehrotra S, Avezaat CJ, Villalon CM, Saxena PR, and Maassenvandenbrink A (2006a) Characterisation of CGRP receptors in the human isolated middle meningeal artery. *Life Sci* **79**:265–271.
- Gupta S, Mehrotra S, Villalon CM, Garrelds IM, de Vries R, van Kats JP, Sharma HS, Saxena PR, and Maassenvandenbrink A (2006b) Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. *Eur J Pharmacol* **530**:107–116.
- Hay DL, Christopoulos G, Christopoulos A, Poyner DR, and Sexton PM (2005) Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. *Mol Pharmacol* **67**:1655–1665.
- Hay DL, Christopoulos G, Christopoulos A, and Sexton PM (2006) Determinants of 1-piperidinecarboxamide, *N*-[2-[[5-amino-*l*-[[4-(4-pyridinyl)-*l*-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2*H*)-quinazolinyl)] (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors—the role of receptor activity modifying protein 1. *Mol Pharmacol* **70**:1984–1991.
- Hay DL, Conner AC, Howitt SG, Takhshid MA, Simms J, Mahmoud K, and Poyner DR (2004) The pharmacology of CGRP-responsive receptors in cultured and transfected cells. *Peptides* **25**:2019–2026.
- Hay DL, Howitt SG, Conner AC, Schindler M, Smith DM, and Poyner DR (2003) CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin_{22–52}, CGRP_{8–37} and BIBN4096BS. *Br J Pharmacol* **140**:477–486.
- Kawase T, Okuda K, and Burns DM (2005) Immature osteoblastic MG63 cells possess two calcitonin gene-related peptide receptor subtypes that respond differently to [Cys(Acm)^{2,7}] calcitonin gene-related peptide and CGRP_{8–37}. *Am J Physiol Cell Physiol* **289**:C811–C818.
- Kuwasaki K, Cao YN, Nagoshi Y, Tsuruda T, Kitamura K, and Eto T (2004) Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins. *Mol Pharmacol* **65**:207–213.
- McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, and Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* **393**:333–339.
- Moreno MJ, Abounader R, Hebert E, Doods H, and Hamel E (2002) Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. *Neuropharmacology* **42**:568–576.
- Nodin C, Vauquelin G, and von Mentzer B (2005) Cys^{2,7}EtaCGRP is a potent agonist for CGRP₁ receptors in SK-N-MC cells. *Biochem Pharmacol* **69**:1235–1240.
- Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, and Foord SM (2002) International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. *Pharmacol Rev* **54**:233–246.
- Sheykhzade M, Lind H, and Edvinsson L (2004) Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries. *Br J Pharmacol* **143**:1066–1073.
- Springer J, Amadesi S, Trevisani M, Harrison S, Dinh QT, McGregor GP, Fischer A, Geppetti P, and Groneberg DA (2004) Effects of α calcitonin gene-related peptide in human bronchial smooth muscle and pulmonary artery. *Regul Pept* **118**:127–134.
- Takhshid MA, Poyner DR, Chabot JG, Fournier A, Ma W, Zheng WH, Owji AA, and Quirion R (2006) Characterization and effects on cAMP accumulation of adrenomedullin and calcitonin gene-related peptide (CGRP) receptors in dissociated rat spinal cord cell culture. *Br J Pharmacol* **148**:459–468.
- Verheggen R, Wojtas K, Webel M, Hoffmann S, and Kaumann AJ (2005) BIBN4096BS and CGRP_{8–37} antagonize the relaxant effects of α -CGRP more than those of β -CGRP in human extracranial arteries. *Naunyn Schmiedebergs Arch Pharmacol* **371**:383–392.
- Waugh DJ, Bockman CS, Smith DD, and Abel PW (1999) Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors. *J Pharmacol Exp Ther* **289**:1419–1426.
- Wunder F, Rebmann A, Geerts A, and Kalthof B (2008) Pharmacological and kinetic characterization of adrenomedullin 1 and calcitonin gene-related peptide 1 receptor reporter cell lines. *Mol Pharmacol* **73**:1235–1243.